Clinical Trials on Latent Tuberculosis Infection in Ireland

Total 1301 results

ActivBiotics

Unknown

PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients

Peripheral Vascular Diseases | Intermittent Claudication

United States, Russian Federation, Brazil
Biogen

Completed

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants (STRIVE)

Relapsing-Remitting Multiple Sclerosis

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

Hereditary Periodic Fevers

Belgium, Italy, Japan, Russian Federation, Turkey, Spain, Germany, United Kingdom, France, United States, Ireland, Israel, Canada, Hungary, Netherlands, Switzerland
Sun Pharmaceutical Industries Limited

Recruiting

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

Psoriatic Arthritis

United States, Australia, Estonia, Japan, Poland, Slovakia, Spain, Taiwan, Czechia, Germany, Korea, Republic of, Italy
National Cancer Institute (NCI)

Recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma

United States, Hong Kong
FibroGen

Terminated

Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, France, United Kingdom, Korea, Republic of, Lebanon, Denmark, China, Italy, Spain, Serbia, Germany, Netherlands, Czechia, Brazil, Poland, Argentina, Colombia, Dominican Republic, Georgia, Hungary, Ireland, Mexico, Peru, Switzerlan... and more
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

Lymphoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Lymphoma

United States, Puerto Rico
Boehringer Ingelheim
Eli Lilly and Company

Completed

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Myocardial Infarction

United States, Spain, Australia, Denmark, Netherlands, Canada, China, Germany, Korea, Republic of, Israel, Hungary, Japan, Argentina, France, Romania, Russian Federation, Serbia, Ukraine, Poland, India, Brazil, Bulgaria
AtheroGenics

Unknown

ARISE - Aggressive Reduction of Inflammation Stops Events

Myocardial Infarction | Coronary Artery Disease | Atherosclerosis | Unstable Angina

Canada, United States, United Kingdom, South Africa
Bristol-Myers Squibb

Active, not recruiting

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Psoriatic Arthritis

Russian Federation, United States, Argentina, Australia, Brazil, Bulgaria, Chile, China, Colombia, Czechia, Finland, France, Hungary, Ireland, Italy, Mexico, Poland, Romania, Spain, Taiwan, United Kingdom
GlaxoSmithKline

Completed

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Anaemia | Aspergillosis, Allergic Bronchopulmonary

Australia, Korea, Republic of, Spain, United States, Taiwan, Bulgaria, Mexico, Ukraine, Argentina, Belgium, South Africa, Singapore, Austria, Canada, Netherlands, Russian Federation, Sweden, Turkey, United Kingdom, Germany, Romania and more
CF Therapeutics Development Network Coordinating...
Cystic Fibrosis Foundation

Completed

The EPIC Observational Study (EPIC OBS)

Cystic Fibrosis

United States
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE COMPLETE)

Psoriatic Arthritis

United States, Australia, Canada, Czechia, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
AstraZeneca

Completed

Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Australia, Canada, New Zealand
Gilead Sciences

Completed

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa (AIR-CF2)

Cystic Fibrosis

United States
UCB Biopharma SRL

Completed

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE READY)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, United Kingdom
AstraZeneca

Completed

Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Australia, Canada, New Zealand
Janssen Research & Development, LLC
Bristol Myers Squibb Company (BMS)

Recruiting

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK)

Ischemic Stroke; Ischemic Attack, Transient

Italy, United States, Hong Kong, Canada, Japan, China, Taiwan, South Africa, Korea, Republic of, Israel, United Kingdom, Argentina, Belgium, New Zealand, Australia, Germany, Czechia, Denmark, Mexico, Croatia, France, Brazil, Hungary, ... and more
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology

Completed

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Amgen

Completed

Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. (FOREMOST)

Arthritis, Psoriatic

United States, Spain, Netherlands, Canada, France, Russian Federation, Belgium, Austria, Germany, Italy, United Kingdom
UCB Biopharma SRL

Completed

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE OPTIMAL)

Psoriatic Arthritis

United States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russian Federation, Spain, United Kingdom
AstraZeneca

Recruiting

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON)

Carcinoma, Non-Small-Cell Lung

United States
Novartis Pharmaceuticals

Completed

Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis (EXCEED 1)

Psoriatic Arthritis

Spain, United Kingdom, Estonia, Hungary, India, Italy, Germany, Israel, United States, Australia, Greece, Bulgaria, Lithuania, Korea, Republic of, Portugal, Russian Federation, Netherlands, France, Czechia, Canada, Poland, Slovakia, Denmar... and more
UCB Biopharma SRL

Active, not recruiting

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE VITAL)

Psoriatic Arthritis

United States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russian Federation, Spain, United Kingdom
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5)

Psoriatic Arthritis

United States, United Kingdom, India, Austria, Denmark, Netherlands, Spain, Germany, Thailand, Israel, Argentina, Greece, Philippines, Latvia, Italy, Guatemala, Russian Federation, Hungary, Ireland, Vietnam, Czechia, Canada, Sweden, M... and more
Amgen

Active, not recruiting

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)

Coronary Heart Disease (CHD)

Canada, France, United States, Spain, United Kingdom, Korea, Republic of, Netherlands, Austria, Australia, Czechia, Taiwan, Finland, Hungary, Italy, Poland, Greece, Germany, Brazil, Latvia, Denmark, Mexico, Russian Federation, Bulgaria and more
AstraZeneca

Completed

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35) (LAS-MD-35)

Chronic Obstructive Pulmonary Disease

United States, Canada
AstraZeneca

Completed

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)

Myocardial Infarction | Stroke | Atherothrombosis | Cardiovascular Death

Sweden, United States, Australia, Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Peru, Poland, Russian Federation, South Africa, Spain, Turkey, United Kingdom, Germany, Philippines, China, Hungary, Romania, U... and more
MedImmune LLC

Completed

A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

Congenital Heart Disease

United States, Spain, United Kingdom, Canada, Belgium, Germany, Israel, Austria, Poland, Russian Federation, Sweden, Lebanon, France, Czech Republic, Hungary, Denmark, Bulgaria
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (FUTURE 1)

Psoriatic Arthritis

Germany, United Kingdom, United States, Belgium, Philippines, Singapore, Thailand, Brazil, Czech Republic, Italy, Argentina, Israel, Russian Federation, Bulgaria, Romania, Australia, Canada, Poland, Slovakia
AstraZeneca

Completed

Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38) (LAS-MD-38)

Chronic Obstructive Pulmonary Disease

United States, Canada
Biogen

Completed

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab (STRATIFY-2)

Relapsing Multiple Sclerosis

United States, Puerto Rico
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) (AROMA)

Chronic Rhinosinusitis With Nasal Polyposis

United States, Italy, Canada, Japan, Germany, Netherlands
Bayer

Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke (OCEANIC-STROKE)

Acute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic Attack

United States, Switzerland, Belgium, Sweden, Canada, Australia, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, Greece, Japan, Turkey, Netherlands, Romania, China, United Kingdom, Portugal, Italy, France, Slovakia, Austria, Czechi... and more
FibroGen

Terminated

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, China, Australia, Korea, Republic of, Taiwan, Russian Federation, Hong Kong, Argentina, Chile
Yale University
National Institute of Neurological Disorders and Stroke (NINDS); Takeda Pharmaceuticals...

Completed

Insulin Resistance Intervention After Stroke Trial (IRIS)

Myocardial Infarction | Stroke | Diabetes

United States, Germany, Israel, Australia, United Kingdom, Canada, Italy, Puerto Rico
Celgene

Completed

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma (ROBUST)

Lymphoma, Large B-Cell, Diffuse

United States, Australia, Belgium, Canada, China, Czechia, France, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Portugal, Puerto Rico, Russian Federation, Spain, Switzerland, Taiwan, Turkey
Cogentus Pharmaceuticals

Terminated

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1) (COGENT-1)

Myocardial Infarction | Coronary Artery Disease | Acute Coronary Syndrome | Percutaneous Coronary Intervention

United States, France, Canada, Australia, Poland, Germany, Italy, Mexico, Romania, Slovakia, Hungary, Czech Republic, Chile, Bulgaria, Puerto Rico, Ukraine
AM-Pharma

Terminated

(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI

Acute Kidney Injury Due to Sepsis

Belgium, Spain, United States, Austria, Denmark, France, United Kingdom, Finland, New Zealand, Australia, Germany, Canada, Netherlands, Ireland, Japan
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Amgen

Completed

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Colon Cancer

United States, Belgium, Canada, Italy, Germany, Spain
Bioniche Life Sciences Inc.

Terminated

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer (EMBARC-RF)

Carcinoma in Situ | Neoplasm Recurrence, Local | Bladder Neoplasm | Mycobacterium | Transitional Cell, Carcinoma

United States, Canada, Poland, Germany, Netherlands, United Kingdom
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer

Lymphoma | Unspecified Adult Solid Tumor, Protocol Specific | Cachexia | Lymphoproliferative Disorder

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Pain | Neuropathy | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian Cancer | Stage IIIB Primary Peritoneal Cancer | Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary... and other conditions

United States
Taiho Oncology, Inc.

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2)

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

United States, Japan, Spain, France, Australia, Italy, Korea, Republic of, United Kingdom, Canada, Germany, Turkey, Hong Kong
Remedy Pharmaceuticals, Inc.

Terminated

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction (CHARM)

Stroke, Acute | Brain Edema

United States, Spain, China, Italy, United Kingdom, Germany, Australia, Hungary, Taiwan, Israel, Canada, Portugal, Korea, Republic of, Czechia, Brazil, Switzerland, France, Belgium, Japan, Lithuania, Croatia, Denmark, Finland, Russian...
National Cancer Institute (NCI)

Recruiting

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Lymphoplasmacytic Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Grade 3b Follicular... and other conditions

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

American Ginseng in Treating Patients With Fatigue Caused by Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Fatigue | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

United States

Clinical Trials on Latent Tuberculosis Infection in Ireland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations